Ustekinumab is a Safe and Effective Biological Agent for Crohn’s Disease in a Liver Transplant Patient
- 31 March 2020
- journal article
- letter
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (10), 1498-1499
- https://doi.org/10.1093/ecco-jcc/jjaa062
Abstract
Matthew Peverelle, MD, B.Biomed, Khashayar Asadi, MD, Peter De Cruz, MBBS, Ph.D, FRACP; Ustekinumab is a safe and effective biologic agent for Crohn’s diseaseKeywords
This publication has 5 references indexed in Scilit:
- Letter Re: Safety of Combination Biologic and Antirejection Therapy Post-liver Transplantation in Patients With Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2020
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2019
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseThe New England Journal of Medicine, 2016
- Ustekinumab is effective and safe in the treatment of Crohn’s disease refractory to anti-TNFα in an orthotopic liver transplant patientJournal of Crohn's and Colitis, 2015
- Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipientsAlimentary Pharmacology & Therapeutics, 2012